To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Please see full Prescribing Information for AREXVY. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

with weakening demand for the Covid-19 products, Pfizer has touted Abrysvo as one of the primary revenue driver. Abrysvo’s ...

mResvia’s prescribing information indicates ... with both GSK and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo in the market.

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work ...

Pfizer gave little information ... this morning that Arexvy had helped the group deliver an “excellent performance” in 2023, adding that it is planning at least 12 major product launches ...

ZORYVE is uniquely formulated as an emollient, water-based product without fragrances or penetration enhancers ... and pediatric patients 6 years of age and older. IMPORTANT SAFETY INFORMATION ZORYVE ...

Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...